A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure
Citation
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. 2013.
| Publication Year | 2013 |
|---|---|
| DOI | 10.1016/j.jacc.2013.05.035 |
| PMID | 23747768 |
Study Details
| Study Design | Randomized controlled trial |
|---|---|
| Evidence Level | Human clinical evidence |
| Sample Size | 512 |
Results
At 12 weeks, 47.95% versus 31.98% achieved at least a 30% NT-proBNP reduction with Qili Qiangxin versus placebo.
Limitations
Short-term biomarker-focused study in a selected adjunctive population.
Related Product
- Qili Qiangxin Capsule